Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT—a clinical comparison
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2191-219X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT—a clinical comparison ; volume:8 ; number:1 ; day:15 ; month:11 ; year:2018 ; pages:1-13 ; date:12.2018
EJNMMI Research ; 8, Heft 1 (15.11.2018), 1-13, 12.2018
- Urheber
-
Jakobson Mo, Susanna
Axelsson, Jan
Jonasson, Lars
Larsson, Anne
Ögren, Mattias J.
Ögren, Margareta
Varrone, Andrea
Eriksson, Linda
Bäckström, David
af Bjerkén, Sara
Linder, Jan
Riklund, Katrine
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13550-018-0450-0
- URN
-
urn:nbn:de:101:1-2018121519313880354200
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jakobson Mo, Susanna
- Axelsson, Jan
- Jonasson, Lars
- Larsson, Anne
- Ögren, Mattias J.
- Ögren, Margareta
- Varrone, Andrea
- Eriksson, Linda
- Bäckström, David
- af Bjerkén, Sara
- Linder, Jan
- Riklund, Katrine
- SpringerLink (Online service)
Ähnliche Objekte (12)
![Influence of CT-based attenuation correction on dopamine transporter SPECT with [123I]FP-CIT](/assets/placeholder/searchResultMediaUnknown.png)
Influence of CT-based attenuation correction on dopamine transporter SPECT with [123I]FP-CIT
Japanese multicenter database of healthy controls for [123I]FP-CIT SPECT
P008 Influence of CT-based attenuation correction on presynaptic dopamine transporter SPECT with 123I-FP-CIT [Abstract]
CYP3A4 inhibitors may influence the quantification of [123I]I-FP-CIT SPECT scans
Relevance of 123I-FP-CIT SPECT prescriptions for the diagnosis of parkinsonian syndromes
Extrastriatal 123I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort
[18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism
123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies
Correction: [18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism
![Prognostische Wertigkeit der [123I]FP-CIT SPECT bei Patienten mit klinischem Verdacht auf eine neurodegenerative Erkrankung](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Prognostische Wertigkeit der [123I]FP-CIT SPECT bei Patienten mit klinischem Verdacht auf eine neurodegenerative Erkrankung
Diagnostic value of micrographia in Parkinson’s disease: a study with [123I]FP-CIT SPECT
No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT
Influence of CT-based attenuation correction on dopamine transporter SPECT with [123I]FP-CIT
Japanese multicenter database of healthy controls for [123I]FP-CIT SPECT
P008 Influence of CT-based attenuation correction on presynaptic dopamine transporter SPECT with 123I-FP-CIT [Abstract]
CYP3A4 inhibitors may influence the quantification of [123I]I-FP-CIT SPECT scans
Relevance of 123I-FP-CIT SPECT prescriptions for the diagnosis of parkinsonian syndromes
Extrastriatal 123I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort
[18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism
123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies
Correction: [18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism
Prognostische Wertigkeit der [123I]FP-CIT SPECT bei Patienten mit klinischem Verdacht auf eine neurodegenerative Erkrankung
Diagnostic value of micrographia in Parkinson’s disease: a study with [123I]FP-CIT SPECT
No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT
Influence of CT-based attenuation correction on dopamine transporter SPECT with [123I]FP-CIT
Japanese multicenter database of healthy controls for [123I]FP-CIT SPECT
P008 Influence of CT-based attenuation correction on presynaptic dopamine transporter SPECT with 123I-FP-CIT [Abstract]
CYP3A4 inhibitors may influence the quantification of [123I]I-FP-CIT SPECT scans
Relevance of 123I-FP-CIT SPECT prescriptions for the diagnosis of parkinsonian syndromes
Extrastriatal 123I-FP-CIT SPECT impairment in Parkinson’s disease – the PPMI cohort
[18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism
123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies
Correction: [18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism
Prognostische Wertigkeit der [123I]FP-CIT SPECT bei Patienten mit klinischem Verdacht auf eine neurodegenerative Erkrankung
Diagnostic value of micrographia in Parkinson’s disease: a study with [123I]FP-CIT SPECT